• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

甲状腺乳头状癌中的RET/PTC激活:欧洲内分泌学杂志获奖讲座

RET/PTC activation in papillary thyroid carcinoma: European Journal of Endocrinology Prize Lecture.

作者信息

Santoro Massimo, Melillo Rosa Marina, Fusco Alfredo

机构信息

Istituto di Endocrinologia ed Oncologia Sperimentale del CNR 'G. Salvatore', c/o Dipartimento di Biologia e Patologia Cellulare e Molecolare, University 'Federico II', Via S. Pansini, 5, 80131 Naples, Italy.

出版信息

Eur J Endocrinol. 2006 Nov;155(5):645-53. doi: 10.1530/eje.1.02289.

DOI:10.1530/eje.1.02289
PMID:17062879
Abstract

Papillary thyroid carcinoma (PTC) is frequently associated with RET gene rearrangements that generate the so-called RET/PTC oncogenes. In this review, we examine the data about the mechanisms of thyroid cell transformation, activation of downstream signal transduction pathways and modulation of gene expression induced by RET/PTC. These findings have advanced our understanding of the processes underlying PTC formation and provide the basis for novel therapeutic approaches to this disease.

摘要

甲状腺乳头状癌(PTC)常与RET基因重排相关,后者可产生所谓的RET/PTC致癌基因。在本综述中,我们研究了有关RET/PTC诱导甲状腺细胞转化机制、下游信号转导通路激活以及基因表达调控的相关数据。这些发现增进了我们对PTC形成过程的理解,并为该疾病的新型治疗方法提供了依据。

相似文献

1
RET/PTC activation in papillary thyroid carcinoma: European Journal of Endocrinology Prize Lecture.甲状腺乳头状癌中的RET/PTC激活:欧洲内分泌学杂志获奖讲座
Eur J Endocrinol. 2006 Nov;155(5):645-53. doi: 10.1530/eje.1.02289.
2
Diffuse sclerosing variant of papillary thyroid carcinoma: major genetic alterations and prognostic implications.甲状腺乳头状癌弥漫性硬化变异型:主要基因改变及预后意义
Histopathology. 2016 Jul;69(1):45-53. doi: 10.1111/his.12902. Epub 2016 Jan 11.
3
Activation of signal transducer and activator of transcription 3 by oncogenic RET/PTC (rearranged in transformation/papillary thyroid carcinoma) tyrosine kinase: roles in specific gene regulation and cellular transformation.致癌性RET/PTC(在转化/甲状腺乳头状癌中重排)酪氨酸激酶激活信号转导及转录激活因子3:在特定基因调控和细胞转化中的作用
Mol Endocrinol. 2003 Jun;17(6):1155-66. doi: 10.1210/me.2002-0401. Epub 2003 Mar 13.
4
Papillary thyroid carcinoma: 6 cases from 2 families with associated lymphocytic thyroiditis harbouring RET/PTC rearrangements.乳头状甲状腺癌:来自2个家族的6例病例,伴有淋巴细胞性甲状腺炎,存在RET/PTC重排。
Br J Cancer. 2001 Dec 14;85(12):1831-7. doi: 10.1054/bjoc.2001.2187.
5
RET/PTC fusion gene rearrangements in Japanese thyroid carcinomas.日本甲状腺癌中的RET/PTC融合基因重排
Eur Arch Otorhinolaryngol. 2005 May;262(5):368-73. doi: 10.1007/s00405-004-0835-8. Epub 2004 Sep 11.
6
20 years of RET/PTC in thyroid cancer: clinico-pathological correlations.甲状腺癌中RET/PTC的20年研究:临床病理相关性
Arq Bras Endocrinol Metabol. 2007 Jul;51(5):731-5. doi: 10.1590/s0004-27302007000500010.
7
A novel RET rearrangement (ACBD5/RET) by pericentric inversion, inv(10)(p12.1;q11.2), in papillary thyroid cancer from an atomic bomb survivor exposed to high-dose radiation.
Oncol Rep. 2014 Nov;32(5):1809-14. doi: 10.3892/or.2014.3449. Epub 2014 Aug 29.
8
[Expressions of wildtype-RET and RET/PTC rearrangements in sporadic adult papillary thyroid carcinoma and their clinicopathologic correlation].[野生型RET及RET/PTC重排在散发性成人甲状腺乳头状癌中的表达及其临床病理相关性]
Zhonghua Bing Li Xue Za Zhi. 2006 Feb;35(2):87-91.
9
Novel rearrangements involving the RET gene in papillary thyroid carcinoma.甲状腺乳头状癌中涉及RET基因的新型重排
Cancer Genet. 2019 Jan;230:13-20. doi: 10.1016/j.cancergen.2018.11.002. Epub 2018 Nov 13.
10
BRAF mediates RET/PTC-induced mitogen-activated protein kinase activation in thyroid cells: functional support for requirement of the RET/PTC-RAS-BRAF pathway in papillary thyroid carcinogenesis.BRAF介导甲状腺细胞中RET/PTC诱导的丝裂原活化蛋白激酶激活:对甲状腺乳头状癌发生中RET/PTC-RAS-BRAF途径需求的功能支持。
Endocrinology. 2006 Feb;147(2):1014-9. doi: 10.1210/en.2005-0280. Epub 2005 Oct 27.

引用本文的文献

1
Advances in lenvatinib monotherapy and combination therapies in anaplastic thyroid cancer (Review).乐伐替尼单药治疗及联合治疗在间变性甲状腺癌中的进展(综述)
Oncol Lett. 2025 Jun 11;30(2):393. doi: 10.3892/ol.2025.15139. eCollection 2025 Aug.
2
Exploring the versatility of as a model organism in biomedical research: a comprehensive review.探索[未提及具体生物]作为生物医学研究模式生物的多功能性:一项综合综述。 (注:原文中“Exploring the versatility of as a model organism”这里缺少具体所指生物)
Fly (Austin). 2025 Dec;19(1):2420453. doi: 10.1080/19336934.2024.2420453. Epub 2024 Dec 25.
3
First-in-human, phase 1 dose-escalation and dose-expansion study of a RET inhibitor SY-5007 in patients with advanced RET-altered solid tumors.
SY-5007 治疗晚期 RET 改变型实体瘤的首次人体、I 期剂量递增和剂量扩展研究。
Signal Transduct Target Ther. 2024 Nov 4;9(1):300. doi: 10.1038/s41392-024-02006-9.
4
Systemic treatments for radioiodine-refractory thyroid cancers.放射性碘难治性甲状腺癌的系统治疗。
Front Endocrinol (Lausanne). 2024 Oct 15;15:1346476. doi: 10.3389/fendo.2024.1346476. eCollection 2024.
5
Case report: First evidence of impressive efficacy of modulated dose selpercatinib in a young Caucasian with ANK3-RET fusion-positive NSCLC.病例报告:在一名患有ANK3-RET融合阳性非小细胞肺癌的年轻白种人中,首次证明了调整剂量的塞尔帕替尼具有显著疗效。
Front Oncol. 2024 Feb 7;14:1307458. doi: 10.3389/fonc.2024.1307458. eCollection 2024.
6
Expression and prognosis analysis of integrin subunit α3 (ITGA3) in papillary thyroid cancer.整合素亚基α3(ITGA3)在甲状腺乳头状癌中的表达及预后分析
Heliyon. 2023 Dec 3;10(1):e23163. doi: 10.1016/j.heliyon.2023.e23163. eCollection 2024 Jan 15.
7
Targeted treatments after chemoradiotherapy failure in a patient with relapsed, advanced non‑small cell lung cancer with on‑therapy circulating tumor biomarker monitoring: A case report.复发性晚期非小细胞肺癌患者放化疗失败后靶向治疗并进行治疗期间循环肿瘤生物标志物监测:一例报告
Oncol Lett. 2023 Aug 2;26(3):407. doi: 10.3892/ol.2023.13993. eCollection 2023 Sep.
8
Mouse Models to Examine Differentiated Thyroid Cancer Pathogenesis: Recent Updates.探讨分化型甲状腺癌发病机制的小鼠模型:最新进展。
Int J Mol Sci. 2023 Jul 6;24(13):11138. doi: 10.3390/ijms241311138.
9
Transcriptomic Analysis Reveals Dysregulation of the Mycobiome and Archaeome and Distinct Oncogenic Characteristics according to Subtype and Gender in Papillary Thyroid Carcinoma.转录组分析揭示了根据甲状腺乳头状癌的亚型和性别失调的真菌组和古菌组以及独特的致癌特征。
Int J Mol Sci. 2023 Feb 5;24(4):3148. doi: 10.3390/ijms24043148.
10
Preclinical Models of Follicular Cell-Derived Thyroid Cancer: An Overview from Cancer Cell Lines to Mouse Models.滤泡细胞源性甲状腺癌的临床前模型:从癌细胞系到小鼠模型的概述。
Endocrinol Metab (Seoul). 2022 Dec;37(6):830-838. doi: 10.3803/EnM.2022.1636. Epub 2022 Dec 26.